Quanterix (NASDAQ:QTRX) Releases Earnings Results, Beats Estimates By $0.16 EPS

Quanterix (NASDAQ:QTRX) released its quarterly earnings results on Monday. The company reported ($0.53) EPS for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.16, Zacks reports. Quanterix had a negative net margin of 30.12% and a negative return on equity of 11.74%. Quanterix updated its FY 2025 guidance to EPS.

Quanterix Stock Up 8.5%

QTRX traded up $0.45 during trading on Monday, reaching $5.73. 529,920 shares of the company’s stock were exchanged, compared to its average volume of 780,423. Quanterix has a fifty-two week low of $4.67 and a fifty-two week high of $19.17. The business has a 50 day moving average price of $6.15 and a 200 day moving average price of $9.06. The company has a market capitalization of $222.26 million, a P/E ratio of -5.41 and a beta of 1.12.

Analysts Set New Price Targets

QTRX has been the topic of several research analyst reports. Leerink Partnrs downgraded shares of Quanterix from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 30th. Scotiabank restated an “outperform” rating on shares of Quanterix in a research note on Tuesday, March 25th. Leerink Partners restated a “market perform” rating and issued a $8.00 price objective (down previously from $12.00) on shares of Quanterix in a research note on Wednesday, April 30th. Finally, Canaccord Genuity Group lowered their price objective on shares of Quanterix from $20.00 to $15.00 and set a “buy” rating on the stock in a research note on Tuesday, March 18th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $16.20.

About Quanterix

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.